• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伤残调整生命年:批判性综述。

Disability-adjusted life years: a critical review.

作者信息

Anand S, Hanson K

机构信息

St. Catherine's College, Oxford, UK.

出版信息

J Health Econ. 1997 Dec;16(6):685-702. doi: 10.1016/s0167-6296(97)00005-2.

DOI:10.1016/s0167-6296(97)00005-2
PMID:10176779
Abstract

The disability-adjusted life year (DALY) has emerged in the international health policy lexicon as a new measure of the 'burden of disease'. We argue that the conceptual and technical basis for DALYs is flawed, and its assumptions and value judgements are open to serious question. In particular, the implications of age-weighting and discounting are found to be unacceptable. Moreover, the proponents of DALYs do not distinguish between the exercises of measuring the burden of disease and of allocating resources. But the appropriate information sets for the two exercises are quite different. Allocating resources by aggregate DALY-minimization is shown to be inequitable.

摘要

伤残调整生命年(DALY)已作为一种衡量“疾病负担”的新指标出现在国际卫生政策词汇表中。我们认为,DALY的概念和技术基础存在缺陷,其假设和价值判断也存在严重问题。特别是,年龄加权和贴现的影响被认为是不可接受的。此外,DALY的支持者没有区分衡量疾病负担和分配资源这两项工作。但这两项工作所需的信息集截然不同。通过使DALY总量最小化来分配资源被证明是不公平的。

相似文献

1
Disability-adjusted life years: a critical review.伤残调整生命年:批判性综述。
J Health Econ. 1997 Dec;16(6):685-702. doi: 10.1016/s0167-6296(97)00005-2.
2
Understanding DALYs (disability-adjusted life years).了解伤残调整生命年(DALYs)。
J Health Econ. 1997 Dec;16(6):703-30. doi: 10.1016/s0167-6296(97)00004-0.
3
Disability Adjusted Life Years (DALYs) and rehabilitation.伤残调整生命年(DALYs)与康复
Disabil Rehabil. 2002 May 10;24(7):378-82. doi: 10.1080/09638280110096269.
4
Health policy approaches to measuring and valuing human life: conceptual and ethical issues.衡量和评估人类生命的卫生政策方法:概念和伦理问题。
Am J Public Health. 1995 Oct;85(10):1356-60. doi: 10.2105/ajph.85.10.1356.
5
Opening the debate on DALYs (disability-adjusted life years).开启关于伤残调整生命年(DALYs)的讨论。
Health Policy Plan. 1996 Jun;11(2):179-83. doi: 10.1093/heapol/11.2.179.
6
Quantifying the burden of disease: the technical basis for disability-adjusted life years.疾病负担的量化:伤残调整生命年的技术基础。
Bull World Health Organ. 1994;72(3):429-45.
7
[Evaluation of the burden of diabetes in Poland].[波兰糖尿病负担评估]
Pol Arch Med Wewn. 2001 Sep;106(3):867-73.
8
Toward a broader view of values in cost-effectiveness analysis of health.迈向健康成本效益分析中更广泛的价值观视角。
Hastings Cent Rep. 1999 May-Jun;29(3):7-15.
9
Theory and methods of economic evaluation of health care.医疗保健经济评估的理论与方法。
Dev Health Econ Public Policy. 1996;4:1-245.
10
Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities.存在外部性时基于成本效用分析进行医疗保健资源分配的影响。
J Health Econ. 1992 Oct;11(3):259-77. doi: 10.1016/0167-6296(92)90003-j.

引用本文的文献

1
Guidelines for the use of economic evaluation to inform policies around access to treatment for kidney failure.利用经济评估为肾衰竭治疗可及性相关政策提供信息的指南。
Nat Rev Nephrol. 2025 Sep 11. doi: 10.1038/s41581-025-01000-w.
2
A Short-Term Cost-Effectiveness Analysis of Tirzepatide Versus Semaglutide for the Treatment of Obesity in Greece.替尔泊肽与司美格鲁肽治疗希腊肥胖症的短期成本效益分析
Healthcare (Basel). 2025 Aug 15;13(16):2011. doi: 10.3390/healthcare13162011.
3
Global, regional, and national burdens of infection over recent decades: a trend analysis informed by the Global Burden of Disease Study.
近几十年来全球、区域和国家的感染负担:基于全球疾病负担研究的趋势分析
Microbiol Spectr. 2025 Jun 3;13(6):e0129024. doi: 10.1128/spectrum.01290-24. Epub 2025 Apr 24.
4
Reevaluating health metrics: Unraveling the limitations of disability-adjusted life years as an indicator in disease burden assessment.重新评估健康指标:剖析伤残调整生命年作为疾病负担评估指标的局限性。
World J Methodol. 2025 Mar 20;15(1):95796. doi: 10.5662/wjm.v15.i1.95796.
5
Navigating the maze of active ageing measurement: untangling methodological and theoretical issues in the UJACAS questionnaire.探索积极老龄化测量的迷宫:厘清UJACAS问卷中的方法学和理论问题。
Aging Clin Exp Res. 2025 Mar 13;37(1):83. doi: 10.1007/s40520-025-02953-5.
6
Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis.司美格鲁肽2.4毫克与利拉鲁肽3毫克治疗希腊肥胖症的短期成本效益分析
Pharmacoecon Open. 2025 May;9(3):487-497. doi: 10.1007/s41669-025-00561-7. Epub 2025 Jan 23.
7
Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses.重新思考结核病发病率量化:成本效益分析中结核病残疾权重的系统评价和批判性评估。
Pharmacoeconomics. 2024 Nov;42(11):1209-1236. doi: 10.1007/s40273-024-01410-x. Epub 2024 Aug 7.
8
Korean National Burden of Disease: The Importance of Diabetes Management.韩国国家疾病负担:糖尿病管理的重要性。
Diabetes Metab J. 2024 Jul;48(4):518-530. doi: 10.4093/dmj.2024.0087. Epub 2024 Jul 26.
9
Estimating the indirect economic burden of cancer in Jordan: a retrospective observational study.评估约旦癌症的间接经济负担:一项回顾性观察研究。
BMJ Open. 2024 Jun 3;14(6):e082025. doi: 10.1136/bmjopen-2023-082025.
10
Applications of Quantitative Microbial Risk Assessment to Respiratory Pathogens and Implications for Uptake in Policy: A State-of-the-Science Review.定量微生物风险评估在呼吸道病原体中的应用及其在政策采纳中的意义:科学综述。
Environ Health Perspect. 2024 May;132(5):56001. doi: 10.1289/EHP12695. Epub 2024 May 10.